New York, NY and Tampa, FL – January 5, 2026 – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, and CanceRx, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships, today announced that the two organizations have entered into…

By Cliff Gibbons, CanceRx Every day, promising life-saving cancer treatments stall in early-stage clinical development, where funding is scarce, timelines are long, and success rates are low. After a research institution, NIH/NCI comprehensive cancer center, or biotech company discovers a new cancer treatment, the drug must then go through rigorous, FDA-approved human testing — Phase…

Challenges for Sites Doing Clinical Trials By Tracy Christianson, CanceRx Clinical Research Consultant From bench research to running trials to setting up new study site networks, I have observed a lot of changes in the clinical development sector. These experiences brought me into contact with a lot of great people over the last few decades…

By Cody Gibbons, Director of Operations, CanceRx CanceRx, an accelerator for clinical development in oncology, has launched a new website to showcase its evolving focus on filling gaps in funding for new cancer therapies. The new website, CanceRx.us, covers the Tampa, Florida, organization’s scientific and business strategy that picks up where public support of…